Bioton

Bioton EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Bioton (BIO.WA) as of Oct 9, 2026 is 179.17. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 16.53 — a change of 984.06% (higher).

EV/FCF

179.17

YoY

984.06%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Bioton is 2025 179.17 . EV/FCF (Enterprise Value to Free Cash Flow) of Bioton was 2024 16.53 . It decreases by 984.06% higher compared to the previous year.

The Bioton EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-29.73 PLN
Jan 1, 2019
-70.99 PLN
Jan 1, 2020
11.99 PLN
Jan 1, 2021
-62.43 PLN
Jan 1, 2022
16.07 PLN
Jan 1, 2023
-93.31 PLN
Jan 1, 2024
16.53 PLN
Jan 1, 2025
179.17 PLN
The Bioton EV/FCF history
YEAREV/FCFYoY
179.17+984.06%
16.53-117.71%
-93.31-680.59%
16.07-125.74%
-62.43-620.76%
11.99-116.89%
-70.99+138.81%
-29.73-7.32%
-32.07-91.85%
-393.36+222.65%
-121.92-425.49%
37.46—
Access this data via the Eulerpool API

Bioton Stock analysis

What does Bioton do? Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioton stock

EV/FCF (Enterprise Value to Free Cash Flow) of Bioton is 179.17 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Bioton changed from 16.53 to 179.17, representing a 984.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Bioton since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Bioton with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Bioton

All Key Metrics — Bioton